Microsatellite Instability Testing
The latest news on microsatellite instability testing.
Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors
European regulators approved the agent for PD-L1-positive cervical cancer and for five tumor types defined by high microsatellite instability or DNA mismatch repair deficiency.
EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in Specific MSI-H/dMMR Tumors
The European committee's recommendation is narrower than the FDA's tissue-agnostic approval for the drug in refractory patients with tumors harboring these biomarkers.
FDA Approves Merck's Keytruda for MSI-H, dMMR Endometrial Cancer With Roche CDx
The agency approved the checkpoint inhibitor for this new indication based on response data from the multi-arm KEYNOTE-158 basket trial.
MD Anderson Researchers Explore Neoadjuvant Keytruda in MSI-high Solid Tumors
The study presented at the ESMO Congress also suggested that ctDNA testing may predict which patients should have surgery to remove their tumors and those who can do without it.
Based on insights gleaned from earlier trials of its Granite and Slate neoantigen immunotherapies, the company is improving the design of its vaccines and homing in on best responders.